Lithium Hydroxide → HCID 178445688, compound

Participants

Reaction Steps

Butyl 1-((trans-4-tert-butylcyclohexyl){[4-(trifluoromethoxy)phenyl]acetyl}amino)indane-5-carboxylate, enantiomer A (55 mg) or enantiomer B (45 mg), was saponified with aqueous LiOH and then coupled to 5-amino tetrazole following the procedure described (Step D., Example 1/2) to give 1-((trans-4-tert-butylcyclohexyl){[4-(trifluoromethoxy)phenyl]acetyl}amino)-N-1H-tetrazol-5-ylindane-5-carboxamide. Enantiomer A: HPLC/MS: m/z=585.2 (M+1), Rt=2.75 min. 1H NMR (DMSO-d6): δ 12.30 (1H, br s), 7.90 (1H, s), 7.85 (1H, d, J=8.0 Hz), 7.31 (4H, s), 7.04 (1H, d, J=8.0 Hz), 4.83 (1H, m), 3.77 (2H, m), 3.37 (1H, m), 2.96 (1H, m), 3.08-3.00 (1H, m), 2.91-2.84 (1H, m), 2.41-2.31 (1H, m), 2.24-2.19 (1H, m), 1.78 (2H, m), 1.61 (2H, m), 1.18-0.95 (4H, m), 0.85 (9H, s). Enantiomer B: HPLC/MS and 1H NMR (DMSO-d6) are identical to those of enantiomer A.

Provenance & Evidence